MedTrace Logo

Calcium for Pre-Eclampsia Prevention (CPEP)

NCT00000534 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2017-03-13

No results posted yet for this study

Summary

To evaluate the efficacy of 2 grams per day of oral calcium supplementation in reducing the combined incidence of hypertensive disorders of pregnancy: pre-eclampsia, eclampsia, and the HELLP Syndrome (hypertension, thrombocytopenia, hemolysis, and abnormal liver function). The National Institute of Child Health and Human Development (NICHD) initiated the trial in 1991, with joint funding provided by the National Heart, Lung, and Blood Institute in fiscal years 1992, 1993, and 1995.

Conditions

Interventions

DRUG

calcium

BEHAVIORAL

dietary supplements

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    lead NIH

Principal Investigators

  • Patrick Catalano · Case Western Reserve University

  • Luis Curet · University of New Mexico

  • John Hauth · University of Alabama at Birmingham

  • Cynthia Morris · Oregon Health and Science University

  • Baha Sibai · University of Tennessee

Study Design

Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-03-31
Completion
2000-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000534 on ClinicalTrials.gov